SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
7th Annual Evercore HealthCONx Conference
December 4, 2024
2:10 p.m. ET – fireside chat
A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com


Đề xuất
Allooloo Tops 100M Capital Markets AI Agent Traffic a Month
KONST Showcases “24/7 GPUs Delivered in Asia” at SC26, Offering AI Compute Services from Validation and Delivery to Round-the-Clock Operations
APEC CEO Summit 2026 Concludes Successfully in Shenzhen
SEGI FRESH STEPS FORWARD TO SUPPORT SELANGOR FLOOD RECOVERY THROUGH RM200,000 JOINT VOUCHER INITIATIVE
Trip.com Group and Tourism Australia’s One Voice Partnership to Turn Growing Global Demand into Wider Discovery Across Australia
Regenerative Aesthetics brand LÖVISELLE Launches at National Gallery Singapore, Under the Theme “Beyond Stimulation, True Regeneration”